ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Aberrantly expressed ncRNAs then activate or suppress molecular pathways implicit in therapy resistance, upregulate drug transporters, regulate BCR::ABL1 expression, and modulate the CML LSC to contribute to therapy resistance in CML.